Biopharma Group(MREO)

UK - WinchesterCDMO (Contract Manufacturing)

Focus: Biopharma Group is a global CDMO specializing in liquid and drying technologies, serving rare disease, oncology, and immunology markets. As a public company (MREO) founded in 1993, they operate at scale but remain focused on contract manufacturing rather than proprietary drug development.

Rare Diseases Oncology Neurology Cardiovascular

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Biopharma Group

AI assessmentNot Hiring

No open roles listed right now. Follow Biopharma Group to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Pipeline & Clinical Trials

A. Ceftriaxone

Healthy

Phase 1

Clinical Trials (1)

NCT03895567Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.

Phase 1

Help build intelligence for Biopharma Group

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline exposure across high-value rare disease and oncology indications (13 active programs, 5 in Phase 3) without single-drug revenue risk
Established public company with 32-year track record and stable cash position ($70M FY2025), providing operational predictability
Specialized CDMO focus in formulation technologies offers deep technical differentiation and advancement potential in drug delivery innovation

Watch Out For

Currently unprofitable with $43.3M net loss (FY2025) and minimal revenue ($10M FY2024), indicating early commercialization stage and potential runway concerns
Zero open job requisitions signal minimal hiring momentum and limited near-term advancement opportunities across the organization

Generated by Claude from Biopharma Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

AX-158

Autoimmune Diseases

Phase 1

STRO-002

Neoplasm Malignant

Phase 1/2

Luveltamab tazevibulin

Acute Myeloid Leukemia (AML)

Phase 1/2

UCB0599

Early-stage Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT04658186A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Phase 2

rNAPc2

Coronary Disease

Phase 2

Clinical Trials (1)

NCT00116012Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

Phase 2

Vamorolone 0.25 mg/day/day

Duchenne Muscular Dystrophy

Phase 2

Clinical Trials (1)

NCT02760277An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)